Heart Disease

$500B+
Global Research Spending
17.9M
Deaths Annually (Global)
76
Years Since Framingham Study
None
Approved Reversal Therapy

The #1 Killer Still Has No Cure

Heart disease is the leading cause of death globally. 17.9 million deaths per year. Over $500 billion spent on cardiovascular research. Stents manage blockages. Statins manage cholesterol. Bypass surgery bypasses the problem. No therapy reverses atherosclerosis. No cure exists.

The Framingham Heart Study began in 1948. Seventy-six years of data on risk factors, progression, and outcomes. We know what causes heart disease. We know how to delay it. We do not know how to reverse it. Treatment focuses on symptom management, not disease reversal.

Framingham Study Launch 1948
First Coronary Bypass Surgery 1967
Statin Drugs Approved 1987
Percutaneous Coronary Intervention (PCI) 2000s
Therapies Reversing Atherosclerosis 0

The Promise vs. Reality Pattern

1948
Science Begins: Framingham Heart Study launched. First large-scale effort to understand cardiovascular disease.
1967
Surgical Intervention: First coronary artery bypass graft performed. Bypass the blockage. Success defined as prolonged survival, not reversal.
1987
Pharmacological Promise: Statins approved. Cholesterol lowering. Plaque growth slowed, not reversed. Hundreds of millions prescribed.
2000s
Interventional Boom: Percutaneous coronary intervention (PCI) becomes standard. Stents placed. Vessels reopened. Atherosclerotic plaque remains.
2020s
Gene Therapy Trials: PCSK9 inhibitors. Gene therapy approaches in early trial phases. Still no approved therapy that reverses existing atherosclerosis.

Current Research Status

Cardiovascular research is funded at the highest level globally. Treatment options continue to expand. Prevention through risk factor management is well-established. A therapy that reverses atherosclerosis has not been developed. Current research focus includes regenerative approaches, gene therapy, and cellular reprogramming. None have achieved approval for reversing plaque burden in human subjects.

Active Cardiovascular Trials 3,500+
PCSK9 Inhibitor Approvals 5
Gene Therapy Approaches In Early Development
Approved Atherosclerosis Reversal Therapies 0

What This Means: Cardiovascular disease is manageable and preventable for many. Medication prevents further plaque formation. Interventions extend life. None of these approaches remove existing plaque or reverse the underlying disease process. Atherosclerosis remains a chronic, manageable condition. It remains incurable.

Sources & Methodology

Data compiled from NIH, WHO, peer-reviewed sources, and clinical trial databases.

Primary Sources

  • National Institutes of Health -- Cardiovascular Research Funding (RePORT Database)
  • World Health Organization -- Global Health Statistics (2023)
  • American Heart Association -- Heart Disease and Stroke Statistics (2023--2024)
  • ClinicalTrials.gov -- Cardiovascular Disease Active Trials (3,500+ trials)
  • Framingham Heart Study -- 76 Years of Longitudinal Data (NIH Collaboration)
  • The Lancet -- Cardiovascular Disease Burden and Treatment (2023)
  • Nature Cardiovascular Research -- Gene Therapy and Regenerative Approaches (2023)